Overview
Tomoko Narita practices in Nagoya, Japan. Ms. Narita is rated as an Experienced expert by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). Her top areas of expertise are Multiple Myeloma, Adult T-Cell Leukemia, Acute Myelomonocytic Leukemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant.
Her clinical research consists of co-authoring 53 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Chronic Myelomonocytic Leukemia (CMML).
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Adult T-Cell LeukemiaMs. Narita isAdvanced. Learn about Adult T-Cell Leukemia.
- Multiple MyelomaMs. Narita isAdvanced. Learn about Multiple Myeloma.
- Experienced
- Acute Megakaryoblastic LeukemiaMs. Narita isExperienced. Learn about Acute Megakaryoblastic Leukemia.
- Acute Myelomonocytic LeukemiaMs. Narita isExperienced. Learn about Acute Myelomonocytic Leukemia.
- B-Cell LymphomaMs. Narita isExperienced. Learn about B-Cell Lymphoma.
- Bone Marrow TransplantMs. Narita isExperienced. Learn about Bone Marrow Transplant.
- Chronic Myelogenous Leukemia (CML)Ms. Narita isExperienced. Learn about Chronic Myelogenous Leukemia (CML).
- Chronic Myelomonocytic Leukemia (CMML)Ms. Narita isExperienced. Learn about Chronic Myelomonocytic Leukemia (CMML).